Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ductal Breast Carcinoma In Situ|HER2/Neu Positive
Interventions: OTHER: Laboratory Biomarker Analysis|DRUG: Lapatinib Ditosylate|OTHER: Placebo
Sponsor: National Cancer Institute (NCI)